Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma

Published:2009-12 Issue:12 Volume:50 Page:2075-2077
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gupta Neel K.¹,Barker Juliet N.²,Young James W.²,Noy Ariela³

Affiliation:

1. Division of Graduate Medical Education, Department of Medicine

2. Adult Allogeneic Bone Marrow Transplant Service

3. Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.3109/10428190903144642

Reference11 articles.

1. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

2. Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma

3. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

4. Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

5. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database;Pathology - Research and Practice;2018-11

2. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation;Biology of Blood and Marrow Transplantation;2010-11

3. Comeback for the camptothecins?;Leukemia & Lymphoma;2009-10-08